UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
| (Exact Name of Registrant as Specified in its Charter) |
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
| (Address of Principal Executive Office) (Zip Code) |
Registrant's telephone number, including
area code: (
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Appointment of Sharon Larkin to Board of Directors
On December 8, 2021, the board of directors (the “Board”) of Senseonics Holdings, Inc. (the “Company”) appointed Sharon Larkin to serve as a director of the Company, which appointment became effective immediately. Ms. Larkin will serve as a Class I director whose term will expire at the 2023 annual meeting of stockholders.
There is no arrangement or understanding between Ms. Larkin and any other person pursuant to which she was selected as a director of the Company, and there is no family relationship between Ms. Larkin and any of the Company’s other directors or executive officers. The Company is not aware of any transaction Ms. Larkin requiring disclosure under Item 404(a) of Regulation S-K. More information about Ms. Larkin is set forth below:
Sharon Larkin, age 58, is a former senior executive of Assertio Therapeutics, Inc., having retired in 2020 as senior vice president, Human Resources and Administration. Ms. Larkin joined Assertio Therapeutics, Inc., in 2017 after retiring from Abbott as divisional vice president, Human Resources, Medical Devices Group, where she provided global human resources leadership for Abbott’s five medical device operating businesses, including Abbott Diabetes Care, Abbott Vascular, Abbott Medical Optics, Abbott Animal Health and Abbott Electrophysiology. Ms. Larkin joined Abbott in 1992 and also held positions of increased responsibility in Abbott’s Nutrition, HealthSystems and Corporate operations. Prior to joining Abbott, Ms. Larkin worked for the Federal Reserve Bank of Atlanta, Jacksonville Branch, where she provided leadership for the branch’s U.S. Treasury securities services and human resources operations. Ms. Larkin received a B.S. in industrial management from the Georgia Institute of Technology.
In connection with her appointment to the Board, Ms. Larkin was appointed as a member of the Board’s Compensation Committee.
On December 8, 2021, Ms. Larkin was granted a restricted stock unit for 72,115 shares of the Company’s common stock, which will vest in three equal annual installments, subject to Ms. Larkin’s continuous service through each such vesting date. In addition, Ms. Larkin will be eligible for an annual retainer of $40,000 for her service as a director and $6,500 for her service as a member of the Compensation Committee, pursuant to the Company’s non-employee director compensation policy.
Ms. Larkin is expected to enter into the Company’s standard form of indemnification agreement with the Company.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| SENSEONICS HOLDINGS, INC. | ||
| Date: December 9, 2021 | ||
| By: | /s/ Nick Tressler | |
| Name: | Nick Tressler | |
| Title: | Chief Financial Officer | |